Abstract CT148: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab plus chemotherapy in patients with advanced solid tumors
Bibliographic record
Abstract
Abstract Background: In the dose escalation phase of a first-in-human phase 1 study (NCT03564691), the anti-ILT4 monoclonal antibody MK-4830 plus pembrolizumab (pembro) had a manageable safety profile and showed promising antitumor activity in participants (pts) with advanced solid tumors. Safety and efficacy for MK-4830 plus pembro plus chemotherapy (chemo) for select cohorts from the expansion phase are presented. Methods: Enrolled pts were aged ≥18 y with high-grade epithelial ovarian cancer and 1-2 prior lines of systemic therapy including ≥1 platinum-based therapy (cohort J); locally recurrent inoperable or metastatic triple-negative breast cancer naive to chemo (cohort K); or previously untreated recurrent advanced mesothelioma (cohort L). All pts received MK-4830 800 mg plus pembro 200 mg IV Q3W for 35 cycles plus chemo (cohort J: paclitaxel 80 mg/m2 [days 1, 8, and 15 Q3W] or docetaxel 75 mg/m2 Q3W or 25 mg/m2 weekly; cohort K: paclitaxel 90 mg/m2 [days 1, 8, and 15 Q4W]; cohort L: pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 Q3W for 6 cycles or carboplatin AUC 5-6 Q3W for 4 cycles). Primary end points included safety and ORR per RECIST v1.1 (cohorts J and K) or modified RECIST (mRECIST; cohort L) by investigator assessment. Exploratory end points included DOR and PFS per RECIST v1.1 (cohorts J and K) or mRECIST (cohort L) by investigator assessment. Results: At data cutoff (Sept 19, 2024), the number of enrolled pts who received treatment was 41 in cohort J, 34 in cohort K, and 42 in cohort L. Median study follow-up was 21.7 mo (range, 13.8-33.0) in cohort J, 16.1 mo (12.1-23.6) in cohort K, and 23.0 mo (14.6-32.7) in cohort L. Treatment-related AEs occurred in 37 pts (90%) in cohort J, 34 pts (100%) in cohort K, and 40 pts (95%) in cohort L; grade 3-5 events occurred in 14 pts (34%), 14 pts (41%), and 19 pts (45%), respectively. Treatment-related AEs led to death in 1 pt in cohort K (lower respiratory tract infection) and 2 pts in cohort L (1 enterocolitis and 1 myopericarditis); no treatment-related deaths occurred in cohort J. Immune-mediated AEs and infusion reactions occurred in 12 pts (29%) in cohort J, 13 (38%) in cohort K, and 13 (31%) in cohort L; grade 3-5 events occurred in 2 (5%), 3 (9%), and 2 (5%) pts, respectively. ORR was 28% (95% CI, 15-44) in cohort J, 32% (17-50) in cohort K, and 38% (24-54) in cohort L; median DOR was 4.1 mo (range, 3.2-11.2), 11.1 mo (2.7-19.5+), and 14.8 mo (3.3-27.3), respectively. Median PFS was 5.0 mo (95% CI, 4.2-5.7), 5.6 mo (3.9-9.3), and 9.7 mo (7.5-13.7), respectively. Conclusions: In pts with select advanced solid tumors, the safety profile observed with MK-4830 plus pembro plus chemo was manageable and consistent with that for each individual therapy. Modest antitumor activity was observed with the addition of MK-4830 to pembro plus chemo. Investigation of other therapies in these difficult-to-treat tumor types is warranted. Citation Format: Rafal Dziadziuszko, Sofia Baka, Eytan Ben Ami, Maria Jose de Miguel Luken, Marta Gil-Martin, John Hilton, Iwona Lugowska, Ruth Perets, Leah Suttner, Douglas C. Wilson, Omobolaji O. Akala, Penelope Bradbury. Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab plus chemotherapy in patients with advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT148.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.002 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.008 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".